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In Swiss prisons, more than 70% of detained people are foreigners and over one-third originate from sub-Saharan Africa or
Latin America. These two regions are endemic for various tropical diseases and viral infections, which persist after migration
to nonendemic countries. Parasitic infections (schistosomiasis; strongyloidiasis) and cooccurrent viral infections (HIV, hepatitis
B (HBV), and hepatitis C (HCV)) are especially of concern for clinical care but have been neglected in empirical research. These
diseases often remain silent for years before causing complications, especially if they occur concomitantly. Our research aimed to
study the prevalence rates and coinfections of two neglected tropical diseases, namely, Strongyloides stercoralis and Schistosoma
sp. and viral infections among sub-Saharan Africans (SSA) and Latin Americans (LA) in Switzerland’s largest pretrial prison.
We carried out a cross-sectional prevalence study using a standardized questionnaire and serological testing. Among the 201
participants, 85.6% were SSA and 14.4% LA. We found the following prevalence ratios: 3.5% of HIV (4.1% in SSA, 0% in LA),
12.4% of chronic HBV (14.5% in SSA, 0% in LA), 2.0% of viraemic HCV (1.7% in SSA, 3.4% in LA), and 8.0% of strongyloidiasis
(8.1% in SSA, 6.9% in LA). The serological prevalence of schistosomiasis among SSA was 20.3% (not endemic in Latin America).
Two infections were simultaneously detected in SSA: 4.7% were coinfected with schistosomiasis and chronic HBV. Four other
coinfections were detected among SSA: schistosomiasis-HIV, HIV-chronic HBV, HIV-HCV, and schistosomiasis-strongyloidiasis.
To conclude, the high prevalence rates of persistent viral and parasitic infections and their potential coinfections among SSA and
LA detained migrants highlight the need to implement control strategies and programs that reach people in detention centers in
nonendemic countries.
1. Introduction
Theglobal prevalence rate of human immunodeficiency virus
(HIV), hepatitis B virus (HBV), and hepatitis C virus (HCV)
approximates, respectively, 0.8%, 3.6%, and 1%, although
their specific disease burden varies considerably between
and within countries and regions [1–3]. These blood-borne
infections remain a major health problem in most countries
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due to their associated morbidity and mortality [4]. Owing
principally to long asymptomatic periods, the prevalence
rates of chronic or persistent viral infections found in immi-
grants is related to the prevalence rates reported in their
countries of origin where they spent part of their lives [5, 6].
Similarly, other infectious pathologies, including
helminthiasis such as strongyloidiasis and schistosomiasis
(both neglected tropical diseases, NTDs), can represent a
persistent health problem among people who have migrated
from endemic countries [7–9]. However, they have been
neglected in epidemiological research. The research on the
burden of infectious diseases among immigrants in Western
countries rarely focuses on NTDs such as schistosomiasis
and strongyloidiasis, probably because they are often a- or
paucisymptomatic and because health professionals rarely
consider these diseases [10].
1.1. Strongyloidiasis. Strongyloidiasis is endemic in tropi-
cal and subtropical regions. In immunocompetent persons,
chronic intestinal infection usually remains paucisymp-
tomatic for decades. In immunocompromised individuals,
larvae can massively invade the gastrointestinal and pul-
monary systems (hyperinfection syndrome) and other organs
(disseminated strongyloidiasis). This invasion facilitates the
translocation of enterobacteria leading to bacterial sepsis [11].
Hyperinfection syndrome and disseminated strongyloidiasis
are severe conditions with high mortality rates (up to 87%)
[12].
1.2. Schistosomiasis. Sub-Saharan Africa is the main endemic
region for schistosomiasis: 93% of world’s cases occur in
this continent (mainly S. mansoni and S. haematobium) [13].
In Latin America, schistosomiasis (S. mansoni) is endemic
only in certain areas of Brazil, Venezuela, Suriname, and
some Caribbean islands [14]. Adult worms concentrate in the
mesenteric (S. mansoni and S. japonicum) and perivesical (S.
haematobium) veins, and the deposition of eggs in host tis-
sues provokes inflammatory and fibrotic reactions. Infected
patients can present abdominal pain, diarrhea, dysenteric
syndromes (intestinal disease) and/or hematuria, dysuria,
secondary infections, and ureteral fibrosis (genitourinary dis-
ease). Eggs can embolize the portal spaces of the liver, causing
progressive fibrosis. One of the most feared complications
is an upper gastrointestinal bleeding caused by esophageal
varices [15].
1.3. Coinfections. Patients coinfected with viral and NTDs
may have a more severe clinical course [5]. Coinfection of
schistosomiasis with chronic HBV and HCV is associated
with more severe forms of liver disease. Schistosomiasis can
increase HIV transmission and accelerates HIV progression
[16–25]. InHIV-infected patients, strongyloides infection can
increase the risk of immune reconstitution syndrome, and
in some circumstances, the risk of strongyloides hyperin-
fection, such as in patients treated with corticosteroids for
toxoplasmosis or pneumonia caused by Pneumocystis carinii
[26]. Data on prevalence rates of coinfections are needed to
implement appropriate public health programs and improve
awareness of health care staff within the prison context.
Therefore, these coinfections should be at focus: patients with
hepatopathy should be screened for schistosomiasis, as well
as immunosuppressed patients for strongyloidiasis, in case of
epidemiological risk factors for these helminths.
1.4. Detention Setting. In Europe, immigrants represent a
high proportion of the correctional population. In 2012, non-
European citizens accounted for 21% of the estimated 1.73
million people detained in the prisons of the 47 Member
States of the Council of Europe. A large majority of for-
eign detainees originated from low-income countries. In
Switzerland, inmates of non-Swiss nationality represent 73%
of the correctional population, which is among the highest
proportion of foreigners in detention in Western European
countries. In the largest pretrial prison of Switzerland, 28%
of detainees were SSA and 9% LA [27, 28]. People in prison
represent a vulnerable and underserved population with
often highmorbidity but limited access to healthcare services
[29, 30]. Therefore, detention settings are an opportunity to
screen for, diagnose, and treat diseases with individual and
sometimes public health (control of transmission) benefits
[29, 31]. Furthermore, migrants from developing countries
often lack access to health care, and therefore studies among
people living in detention provide invaluable information for
this underserved population.
The prevalence rates of blood-borne viruses are reported
to be higher in prison settings than in the community.
The main risk factors include history of injecting drug use,
unprotected sexual intercourse, and unsafe tattooing [32].
There is limited knowledge on the relationship between
migration to a nonendemic country and the epidemiologic
profile of other infectious diseases, in particular persistent
parasitic infections, among inmates from endemic regions.
Therefore, our study aimed to explore the epidemiologic
profile of strongyloidiasis, schistosomiasis, HIV, HBV, and
HCV among people from sub-Saharan Africa and Latin
America who are detained in the pretrial detention center in
Geneva, Switzerland.
2. Methods
2.1. Study Design, Population, and Setting. We used a cross-
sectional study, which took place in 2015 at the pretrial deten-
tion center of Champ-Dollon (Geneva), the largest correc-
tional center in Switzerland. The report of our study findings
are based on the STROBE statement. Through an informa-
tion campaign conducted in the detention center, all adults
originating from Latin American or sub-Saharan African
countries were invited to participate in the study. Interested
individuals received information about the research and
signed an informed consent form before study inclusion. A
trained researcher administered a standardized questionnaire
to each participant, whereupon a nurse collected a blood
sample of circa 10 ml. We calculated the sample size (to
decide the minimal number of participants that should be
included in the study) according to the expected prevalence
rates of strongyloidiasis and schistosomiasis, the core focus of
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the study. The expected prevalence rates for strongyloidiasis
and schistosomiasis were estimated at 10% and 15% using a
pilot study at Geneva correctional center [5] and prevalence
rates among migrants in Europe [33–36]. With a +/-6%
margin error and a confidence interval of 95%, the minimal
sample sizes were, respectively, 97 and 137 participants for
strongyloidiasis and schistosomiasis [37].
2.2. Questionnaire. Participants answered a standardized
questionnaire in Spanish, Portuguese, English, or French
(the interviewer was competent in these languages) (see
Supplementary S1 Questionnaire). An initial short version
of the questionnaire was offered to the first 30 participants,
after which a longer version was finalized with additional
questions. Questions explored sociodemographic character-
istics (age, sex, country of birth, economic situation in the
country of origin, and education level), sanitation conditions,
and exposure to factors potentially related to viral infections
(past and current injecting drug use, sexual behavior, body
piercing other than ear-piercing and blood transfusion), and
parasitic infections (walking barefoot in mud, swimming in
lakes or rivers, and history of red urine during childhood).
2.3. Blood Sampling. Serological testing was performed at the
Geneva university hospitals laboratory for viral diagnoses
and at Unilabs laboratory (Coppet, Switzerland) for parasitic
diagnoses. Serum samples were tested for HBV surface
antigen (HBsAg), antibodies against HBV core antigen (anti-
HBc), and surface antigen (anti-HBs), anti-HIV, and anti-
HCV using commercial immunoenzymatic assays (Abbott
Laboratories SA). Anti-HIV were systematically confirmed
by INNO-LIA HIV I/II Score (Innogenetics, Belgium).
Anti-HCV reactivity was systematically confirmed by INNO-
LIA HCV Score (Innogenetics, Belgium) and quantitative
HCV RNA measurements (Cobas Ampliprep TaqMan, v2.0,
Roche Molecular Systems). The presence of these three
positive tests signaled an active HCV infection. HBsAg
positivity signaled a chronic HBV infection. The presence of
anti-HBc antibodies and negativeHBsAg indicated a resolved
infection. Among participants with a serological pattern
compatible with a resolved HBV (anti-HBc pos/HbsAg neg),
occult HBV infections were not excluded. Since these cases
are rare, underevaluation of chronic HBV prevalence rate in
the study population would be very limited [38].
Screenings for strongyloidiasis and schistosomiasis were
done using two ELISA commercial kits (Bordier Affinity
Products SA, Switzerland). Bordier-ELISA kits for the diag-
nosis of schistosomiasis are reported to detect 94% of both
Schistosoma mansoni and Schistosoma haematobium with
a specificity of 94% in patients also coinfected with other
helminths [39, 40]. Screening for schistosomiasis was per-
formed using serum of all SSA and four LA (only those orig-
inating from endemic countries). The serologic test, Bordier-
ELISA, for the detection of Strongyloides stercoralis has a
sensitivity of 91% and a specificity of 94% among a composite
population, which includes individuals from tropical areas
who are coinfected with other parasitic infections [41]. All
serological testing and screenings were performed according
to the instructions from the manufacturers (Abbott, Inno-
genetics, Cobas, Bordier affinity products).
2.4. Clinical Management of Participants. All participants
with confirmed HIV, HBV, HCV, schistosomiasis, and
strongyloidiasis underwent a clinical evaluation. In cases of
HIV, chronic HBV, and HCV, patients were referred to the
Geneva university hospitals for specialized care. Antiparasitic
treatments were given to participants who were positive
for schistosomiasis (praziquantel 40mg/kg, once) and for
strongyloidiasis (ivermectin 0.2mg/kg, once daily for two
days). Vaccination against HBV was proposed to susceptible
participants (i.e., anti-HBc and anti-HBs negative).
2.5. Statistical Analysis. Thedata were compiled into an Excel
spreadsheet (see Supplementary S1 Dataset). We applied
descriptive statistics using OpenEpi (version 3.01). Continu-
ous variables were summarized as means and standard devi-
ations and categorical variables were summarized as absolute
and relative frequencies. Confidence intervals of prevalence
ratios (95% CI) were calculated using Wilson’s score interval.
Chi-square and Fisher exact tests (when the assumptions of
the chi-square test were not met) were used to explore the
associations between infections and patients’ characteristics.
We also provided odd-ratios. Participants who answered “I
don’t know” or “I do not wish to answer” were not included
in the related analyses. Due to the limited number of partic-
ipants infected with HIV (n=7) and HCV (n=4), we did not
investigate associations of these viral infectionswith potential
risk factors. With regard to parasitic infections, association
with swimming in lakes or rivers, history of red urine during
childhood (for schistosomiasis), andwalking barefoot inmud
(for strongyloidiasis) were explored. A two-sided p-value less
than to 0.05 was considered to be statistically significant.
2.6. Ethics Statement. The research project protocol was
approved by the Ethics Committee of Geneva (number: 15-
032; April 9, 2015).
3. Results
3.1. Participant Characteristics. Out of 403 inmates invited,
201 consented to participate in the study, answered the
questionnaire, and completed blood analyses (participation
rate: 49.9%). A total of 85.6% were SSA (23 countries) and
14.4% were LA (12 countries). A large majority of SSA
participants originated from West or Central Africa (94.8%)
(Table 1).
Table 2 summarizes the participants’ sociodemographic
characteristics. A total of 93.5% of participants were male,
and 36.2% never attended school or had just reached primary
school level. About a third reported having reading and/or
writing difficulties. Reading inability or difficulties weremore
frequent among SSA participants (34.5%) than among LA
(6.9%) (p<0.01).
With regard to factors potentially related to parasitic
infections, the sanitation conditions before migration dif-
fered among participants from different regions: 96.5% of LA
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Table 1: Participants’ countries of origin, Champ-Dollon detention










aGuinea-Conakry (49), Nigeria (27), Guinea-Bissau (23), Gambia (21),
Senegal (12), Ivory-Coast (5), Liberia (4),Mali (4), Niger (3), Sierra-Leon (3),
Benin (1), Burkina-Faso (1), and Capo-Verde (1).
bCameroon (3), RDC (3), Congo-Brazzaville (1), Gabon (1), and Central
Africa Rep (1).
cSoudan (4), Somalia (1), and Ethiopia (1)
dAngola (2) and Tanzania (1)
eBolivia (4), Chile (3), Colombia (3), Peru (3), Brazil (2), Venezuela (2), and
Paraguay (1).
fDominican Republic (7), Cuba (1), Jamaica (1), Mexico (1), and Nicaragua
(1).
and 52.8% of SSA had indoor toilets (p<0.01) and 96.5% of
LA reported having indoor tap water compared to 40.8% of
SSA (p<0.01).
Regarding factors potentially related to viral infections,
only one SSA participant (0.6%) and one LA (3.5%) reported
a history of injecting drugs. More LA than SSA reported
having tattoos (65.5% versus 11.8%, p<0.001), as well as body
piercing (27.6% versus 0.7%, p<0.001). A history of blood
transfusion was reported by 4.7% of the participants. In terms
of sexual risk factors, 45.2% of males reported a history
of transactional sex (against money or other favors). Half
of the participants (49.8%) reported using condoms most
of the time or always. Among the 156 male participants
who reported being sexually active prior to detention, 98.7%
reported being solely heterosexual.
3.2. Prevalence of Infection according to Origin. Table 3
presents the serological prevalence rates of strongyloidiasis,
schistosomiasis, HIV, HBV, and HCV. A total of 3.5% of
all participants were found to be HIV-positive: 4.1% among
SSA and none among LA. Reflecting chronic or resolved
HBV, 63.7% of participants had a positive anti-HBc: 72.7%
among SSA, 10.3% among LA (p<0.001). The prevalence of
chronic HBV was 12.4%: 14.5% among SSA, 0% among LA
(p<0.03). Susceptibility to HBV (anti-HBc-negative, anti-
HBs-negative) concerned 75.9% of LA and 18.6% of SSA
(p<0.001), and 8.7% of SSA and 13.8% of LA had markers
of HBV vaccinations (anti-HBc-negative, anti-HBs-positive).
The prevalence rate of active HCV was 2.0%: 1.7% among
SSA (2 cases of genotype 4 and one of genotype 2) and 3.4%
among LA (1 case of genotype 1a) (p=0.93). A total of 42.9%
(IC 95% 15.8-74.9) of participants who tested positive forHIV
did not know their serostatus, 52.0% (IC 95% 33.5-70.0) of
participants positive for chronic HBV, and 75.0% (IC 95%
24.2-98.8%) positive for HCV.
The serological prevalence rate of strongyloidiasis was
8.0%: 8.1% among SSA and 6.9% among LA (p=0.99). The
serological prevalence rate of schistosomiasis, calculated
among participants originating from sub-Saharan Africa
(endemic area), was 20.3%.
3.3. Coinfections. Coinfections were detected only among
SSA: 4.7% were coinfected with schistosomiasis and chronic
HBV, 0.6% with schistosomiasis and HIV, 0.6% with HIV
and chronic HBV, 0.6% with HIV and HCV, and 0.6% with
schistosomiasis and strongyloidiasis.
3.4. Association with Sociodemographics, Lifestyle, and Expo-
sure Factors. Among SSA participants, chronic or resolved
HBV infection (anti-HBc-positive) was not significantly
associated with age, education level, socioeconomic status,
number of sexual partners, use of condom, or transactional
sex (see S2 Table).
Among the four participants who were HCV positive, no
one reported a history of injecting drugs or having tattoos or
body piercing. Only one of them reported a history of blood
transfusion.
Reporting history of “red urine during childhood” tended
to be associated with schistosomiasis among SSA partici-
pants, although the association did not reach statistical sig-
nificance (30% versus 17.9%; p=0.1). History of swimming in
lakes or rivers wasmarginally associated with schistosomiasis
(23.0% versus 10.8%; p=0.1) (see Supplementary S2 Table).
4. Discussion
Thiswas the first study conducted in a prison setting designed
to identify strongyloidiasis and schistosomiasis prevalence
rates in Europe and their association with HIV, HBV, and
HCV.
4.1. Epidemiology of Strongyloidiasis and Schistosomiasis. Our
study in Swiss prison showed that a high proportion of
migrants in detention from these endemic regions have par-
asitic NTDs (schistosomiasis seroprevalence: 20.3% among
SSA, strongyloidiasis seroprevalence: 8% among SSA and
LA). These findings corroborated the results from published
literature on persistent parasitic diseases among migrants
(schistosomiasis: 11–44%; strongyloidiasis: 7.5-42%), but
focused on a neglected sub-group of migrants in Europe,
i.e., detainees [13, 33–36, 42–47]. Cases previously reported
in high-income country prisons are rare: only one schis-
tosomiasis case in Spain [48] and no strongyloidiasis case
since 1988, when Bourée et al. [26] described infections
among Africans incarcerated in France. The high prevalence
rates in our sample suggest mis- or underdiagnosis in this
population, probably due to several factors. Strongyloidiasis
and schistosomiasis are usually associated with no or a
specific clinical presentation and require specialized diag-
nostic testing (coproparasitology and serology). Moreover,
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Table 2: Sociodemographic characteristics and factors potentially related to viral and parasitic infections, Champ-Dollon detention center,
Geneva, Switzerland, 2014-2015.
Characteristics TOTAL (n=201) African (n=172) Latinos (n=29)
Age
mean in years (SD) 32.2 (± 9.4) 31.2 (±8.5) 38.4 (±11.8)
Gender
Male 188 (93.5%) 163 (94.8%) 25 (86.2%)
Female 13 (6.5%) 9 (5.2%) 4 (13.8%)
Residence in country of origin
Urban 146 (72.6%) 123 (71.5%) 23 (79.3%)
Rural 55 (27.4%) 49 (28.5%) 6 (20.7%)
Years living in Europe
Mean in years (SD) 10.2 (7.7) 9.7 (7.1) 13.4 (9.0)
Education level1
Never attended school 25 (14.6%) 25 (17.6%) 0 (0%)
Primary 37 (21.6%) 33 (23.2%) 4 (13.8%)
Secondary 95 (55.5%) 77 (54.2%) 18 (62.1%)
University 14 (8.2%) 7 (4.9%) 7 (24.1%)
Self rated socio-economical class1,2
High 3 (1.8%) 3 (2.2%) 0 (0%)
Middle 112 (67.5%) 88 (64.2%) 24 (82.8%)
Low 51 (30.7%) 46 (33.6%) 5 (17.2%)
Reading capacity1
Don’t know how to read 22 (12.9%) 22 (15.5%) 0 (0%)
Read with difficulty 29 (17.0%) 27 (19.0%) 2 (6.9%)
Read without difficulty 120 (70.1%) 93 (65.5%) 27 (93.1%)
Writing capacity1
Don’t know how to write 24 (14.0%) 24 (16.9%) 0 (0%)
Write with difficulty 29 (17.0%) 26 (18.3%) 3 (10.3%)
Write without difficulty 118 (69.0%) 92 (64.8%) 26 (89.7%)
Inside house lavatory
Yes 103 (60.2%) 75(52.8%) 28 (96.6%)
No 68 (39.8) 67 (47.2%) 1 (3.4%)
Indoor tap water
Yes 86 (50.3%) 58 (40.8%) 28 (96.6%)
No 85 (49.7%) 84 (59.2%) 1 (3.4%)
Injecting drugs1
Yes 2 (1.2%) 1 (0.7%) 1 (3.5%)
No 169 (98.8%) 141 (99.3%) 28 (96.5%)
Tattooing1
Yes 36 (21.1%) 17 (12.0%) 19 (65.5%)
No 135 (78.9%) 125 (88%) 10 (34.5%)
Body piercing1
Yes 9 (5.3%) 1 (0.7%) 8 (27.6%)
No 162 (94.7%) 141 (99.3%) 21 (72.4%)
Number of sexual partners1,3
0 3 (1.5%) 3 (1.7%) 0
1-5 44 (27.9%) 41 (31.8%) 3 (10.7%)
6-20 55 (34.4%) 43 (32.5%) 12 (42.9%)
≥21 58 (36.2%) 45 (34.1%) 13 (46.4%)
History of transactional sex1,4
Yes 70 (45.2%) 59 (45.4%) 11 (44.0%)
No 85 (54.8%) 71(54.6) 14 (56%)
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Table 2: Continued.
Characteristics TOTAL (n=201) African (n=172) Latinos (n=29)
Use of condom1
Never- sometimes 85 (50.6%) 68 (48.9%) 17 (58.6%)
Most of times- always 83(49.4%) 71 (51.1%) 12 (41.4%)
Sexual behaviour1,4
Reported sexual contact with same-sex partner/s’ 2 (1.3%) 1(0.8%) 1(4.0%)
Reported sexual contact only with opposite-sex partners’ 154 (98.7%) 130 (99.2%) 24(96%)
History of blood transfusion1
Yes 8(4.6%) 7 (4.9%) 1(3.4%)
No 164 (95.4%) 136 (95.1%) 28 (96.6%)
Walk in mudin country of origin1
Never or rarely 119 (69.6%) 98 (69.0%) 21 (72.4%)
Often 52 (30.4%) 44 (31.0%) 8 (27.6%)
Swim in lakes or rivers in country of origin
Never 46 (23.0%) 37 (21.5%) 9 (32.1%)
Rarely, sometimes or often 154 (77.0%) 135 (78.5%) 19 (67.8%)
1Not included in the initial questionnaire which was administered to the first 30 participants. 25 participants responded “I don’t know”. 3No response for 11
participants (answer: I do not wish to respond). 4Including only males with sexual activity.
Table 3: Serological prevalence of strongyloidiasis, schistosomiasis, HIV, hepatitis B virus (HBV), and hepatitis C virus (HCV) among 201
participants from sub-Saharan Africa and Latin America, Champ-Dollon detention center, Geneva, Switzerland, 2014-2015.
TOTAL Sub-Saharan Africans Latino
n=201 % (95% CI) n=172 % (95% CI) n=29 % (95% CI) p-value (𝜒2)
Strongyloidiasis 16 8.0 (5.0-12.5) 14 8.1 (4.9-13.2) 2 6.9 (1.9-22.0) 0.992
Schistosomiasis - - 35 20.3 (15.0-27.0) - Not endemic1 -
Anti-HIV+ 7 3.5 (1.7-7.0) 7 4.1 (2.0-8.2) 0 0 (0-11.7) 0.662
Chronic/resolved HBV (anti-HBc+) 128 63.7 (56.9-70.1) 125 72.7 (65.6-78.8) 3 10.3 (3.6-26.4) <0.001
Chronic HBV 25 12.4 (8.6-17.7) 25 14.5 (10.0 -20.6) 0 0 (0-11.7) 0.032
(HBsAg+)
Viraemic HCV 4 2.0 (0.8-5.0) 3 1.7 (0.6-5.0) 1 3.4 (0.6-17.2) 0.932
1 In Latin America, transmission of schistosomiasis only in Brazil, Venezuela, and Suriname: none of the four participants originating from these countries
were positive. 2 Fisher exact tests were performed.
cases may be underreported in nonendemic countries, as
helminthic infections are not subject tomandatory reporting.
4.2. Epidemiology of Blood-Borne Infections. The study pop-
ulation’s prevalence ratio was 3.5% for HIV, 12.4% for chronic
HBV, and 2.0% for viraemic HCV. These prevalence rates
were higher than the respective prevalence rates in the
Swiss general population (HIV: 0.2%, HBV: 0.18%, and HCV:
0.71%) [1, 49, 50]. These higher prevalence rates could be
explained by exposure to and acquisition of these infections
in the country of origin and the accumulation of unfavorable
negative social determinants of health along the life course
[32]. In our study population, a correlation with endemicity
in the countries of origin was probable, as participants lived
on averagemore than two-thirds of their lives in their country
of origin.
The observed prevalence ratios of blood-borne infections
among our participants were similar to the expected preva-
lence rates in the general population of the regions of origin.
With regard toHIV, the expected prevalence rate is 3% in sub-
Saharan Africa and 0.3% in Latin America and the Caribbean
[2]. We found, respectively, prevalence ratios of 4.1% and 0%
in our study.
For chronic HBV, the expected prevalence rate is 11.2%
in West and Central Africa (14.5% in our study) and 0.8%
in Latin America (0% in our study) [1]. Sexual health risk
factors (number of sexual partners, history of activity with
sexworkers, and “nonuse” of condoms) were not significantly
related to HBV in our study. It was possible that the sensitive
nature of these questions led to an underreporting of these
sexual behaviors.This underscored that asking these sensitive
questions to migrant populations in prison may not always
be useful in order to identify at-risk groups for HBV. The
proportion of the study population susceptible to HBV
(anti-HBc and anti-HBs negative) also varied according to
origin. Only 9.4% of participants had markers of previous
vaccinations, so catch-up vaccinations are recommended in
prison settings [51].
Journal of Tropical Medicine 7
The similarity between the prevalence rates in our study
and the region of origin also applied to HCV. The global
prevalence rate of viraemic HCV is estimated to be 1.5%
in Western and Central sub-Saharan Africa in the general
population [3].We identified a prevalence rate of 1.7% among
SSA participants, of whom 95%originated fromWestern and
Central sub-Saharan Africa. In high-income countries, HCV
seroprevalence in the correctional population is 10 to 20 times
higher than that in the community, the main risk factor being
intravenous drug use [32, 51]. Also, current HCV control
programs in prisons mainly target people who inject drugs.
The fact that none of the four HCV-positive participants
reported a history of intravenous drug use reinforces the
importance of considering origin as an independent risk fac-
tor among migrants. Acquisition of HCVmay be attributable
to unsafe blood transfusion, as reported by one participant,
or to other well-known risk factors not investigated in the
study, such as unsafe medical injections or exposure to
contaminated blood, among others [52]. Genotypes 2 and
4 are related to 75% of HCV in Western and Central sub-
Saharan Africa. These 2 serotypes are associated with only
13% of chronic HCV in Western Europe [3]. Two cases of
serotypes 4 and one case of serotype 2 were diagnosed in
the SSA participants (100%of infected SSA).This observation
again indicated probable infections acquired in the country of
origin prior to the migration process. Our findings suggested
that control screenings should also target migrants without
an intravenous drug use history originating from highly
endemic countries. From a public health perspective, the
high proportion of participants who tested positive for HIV,
chronic HBV, or viraemic HCV and who did not know
their serostatus confirms that incarceration represents an
opportunity to screen for BBD in the study population. Prison
is also an opportunity to develop public health campaigns
designed to increase knowledge of transmission and control
of infectious diseases, which may be useful upon release.
Further studies should investigate more precisely the extent
of awareness and health-seeking behaviors among inmates.
A better understanding of their current knowledge and
attention to such diseases would help to design effective
interventions.
4.3. Epidemiology of Coinfections. A total of 4.7% of SSA par-
ticipants had schistosomiasis and chronic HBV coinfection,
and 0.6% had schistosomiasis and HIV coinfection. Detec-
tion and treatment of schistosomiasis are recommended
for HIV-, HBV-, or HCV-positive persons with epidemio-
logical risk factors. Indeed, schistosomiasis accelerates the
development of liver fibrosis concomitantly with HBV or
HCV infections and can increase the likelihood of HIV
transmission, aswell as accelerate the progression ofHIV [16–
25]. Treatment of schistosomiasis with praziquantel is well-
tolerated and generally highly effective [15].
The correctional population is characterized by higher
morbidity when compared to the host community [30]
and special attention should be given to migrants from
strongyloidiasis-endemic countries to detect and manage
comorbidities that may precipitate hyperinfection syn-
drome/disseminated strongyloidiasis. These comorbidities
include malignancies, human T-lymphotropic virus type 1
infection, diabetes mellitus, alcohol abuse, and severe mal-
nutrition, in addition to the regular use of corticosteroids.
Moreover, HIV infection predisposes individuals to hyper-
infection syndrome/disseminated strongyloidiasis under cer-
tain conditions (e.g., immune reconstitution syndrome or
opportunistic infections requiring corticoid prescription)
[36, 53–55].Therefore, coinfections and comorbidities should
be at focus, because they have a severe burden of disease.
Furthermore, treatment of uncomplicated strongyloidiasis is
simple and highly effective and can be potentially life-saving
before immunosuppressive therapy [56].
Two of the participants who were HIV-positive and were
not injecting drug users had concomitant infections: one
with HBV (HIV/HBV coinfection) and the other with HCV
(HIV/HCV coinfection). Thus, these coinfections were not
frequent but could be clinically important. HIV accelerates
the natural course of HBV and HCV infection, facilitating
faster liver fibrosis and malignancy [57]. Early diagnosis
and treatment of coinfections are critical. In the case of an
HIV/HBV coinfection, combination antiretroviral therapy
(cART), which includes active agents against both HIV
and HBV (HBV-active cART), significantly reduces liver-
related mortality rates [58]. In the case of an HIV/HCV
coinfection, direct-acting antiviral-based regimens against
HCV are highly effective in HIV patients and can prevent the
HIV/HCV-mediated acceleration of liver disease, which is a
leading cause of morbidity and mortality [59].
4.4. Strengths and Weaknesses. First, the relatively small
sample size limited the extension of statistical analyses to
test associations between variables. However, the main study
objective was not to confirm well-known risk factors of viral
and parasitic diseases, but to investigate at a descriptive
level the prevalence rates of selected parasitic NTDs and
common viral infections. Second, the relatively low partic-
ipation rate may have induced some degree of selection
bias: questions about sex and sexual behavior are sensitive
and many African Muslim participants refused to answer
such questions; individuals of Muslim faith refused blood
sampling during Ramadan; and the interviewer was a woman
(for a largely male population). Therefore, there might be an
underestimation of the prevalence rates of viral infections.
We did not expect any influence on the prevalence rates of
NTD. A third shortcoming was that the small sample size
of prisoners having blood-borne and NTDs may have led
to a lack of power when analyzing their associations with
risk factors. Further studies using larger sample sizes should
test whether migrant status and risk factors are cumulative
risk factors for these diseases. In high-income countries, it
would be useful to investigate whether the prevalence rates
of persistent viral and NTDs among migrants in the general
population correspond to that of incarcerated migrants.
5. Conclusion
The prevalence rates of viral infections, strongyloidiasis, and
schistosomiasis were worryingly high in the studied prison
8 Journal of Tropical Medicine
population. Therefore, persistent parasitic NTDs should no
longer be overlooked in custodial settings hosting migrants
from endemic regions. Control efforts should target migrants
originating from highly endemic countries. Indeed, correc-
tional settings offer an opportunity to implement infectious
disease control programs for a vulnerable populationwho has
limited access to health care. Early diagnoses and treatments
limit complications and costs for both patients and the host
community. Therefore, detention settings must be part of
the agenda for achieving target 3.3 of the United Nations
Sustainable Development Goals, as it aims to end the NTDs
epidemics and combat hepatitis among others.
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